ALT5 Sigma Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Peter Tassiopoulos

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	4.9yrs
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now

Oct 03

Recent updates

Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet?

Nov 15

JanOne Inc.'s (NASDAQ:JAN) Share Price Boosted 153% But Its Business Prospects Need A Lift Too

Mar 31

JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry

Feb 14

Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now

Oct 03

CEO

Peter Tassiopoulos (55 yo)

less than a year

Görev süresi

Mr. Peter Tassiopoulos is Chief Executive Officer of ALT5 Sigma Corporation from August 2024. Mr. Tassiopoulos brings over many years of leadership experience across the healthcare, finance and technology...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Tony Isaac	President	9.5yrs	US$817.71k	1.91% $ 534.4k
Virland Johnson	Chief Financial Officer	7.3yrs	US$349.35k	0% $ 0
Peter Tassiopoulos	Chief Executive Officer	less than a year	Veri yok	Veri yok
Tony Giordano	Chief Scientific Officer	4.9yrs	Veri yok	Veri yok
Douglas Flanagan	Chief Formulation Advisor	4.4yrs	Veri yok	Veri yok

4.9yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim: ALTS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Tony Isaac	President	9.5yrs	US$817.71k	1.91% $ 534.4k
Richard Butler	Independent Director	9.5yrs	US$30.00k	0.11% $ 30.7k
John Cooke	Member of Scientific Advisory Board	4.3yrs	Veri yok	Veri yok
Nicholas Goeders	Member of Scientific Advisory Board	3.4yrs	Veri yok	Veri yok
Christopher Kevil	Chair of Scientific Advisory Board	4.8yrs	Veri yok	Veri yok
Edgar Ross	Member of Scientific Advisory Board	4.3yrs	Veri yok	Veri yok
Nael Hajjar	Independent Director	6.3yrs	US$14.40k	Veri yok
John Bitar	Independent Director	4.8yrs	US$18.00k	0.016% $ 4.4k
Ron Pitters	Independent Director	no data	Veri yok	Veri yok
Joshua Beckman	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ALTS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

ALT5 Sigma Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

ALT5 Sigma Corporation Appoints Ron Pitters to Its Board of Directors

ALT5 Sigma Corporation, Annual General Meeting, Dec 18, 2024

ALT5 Sigma Corporation Announces Chief Executive Officer Changes

Insufficient new directors

Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now

Recent updates

Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet?

New major risk - Revenue and earnings growth

High number of new directors

ALT5 Sigma Corporation Appoints Ron Pitters to Its Board of Directors

ALT5 Sigma Corporation, Annual General Meeting, Dec 18, 2024

ALT5 Sigma Corporation Announces Chief Executive Officer Changes

ALT5 Sigma Corporation announced delayed 10-Q filing

Insufficient new directors

JanOne Regains Compliance with Nasdaq's Listing Rule 5550(b)(1)

JanOne Inc. (NasdaqCM:JAN) completed the acquisition of Alt 5 Sigma Inc.

JanOne Inc.'s (NASDAQ:JAN) Share Price Boosted 153% But Its Business Prospects Need A Lift Too

JanOne Inc. announced delayed annual 10-K filing

JanOne Regains Compliance with Nasdaq’s Listing Requirements

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 93%

JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry

New minor risk - Profit margin trend

New major risk - Shareholder dilution

New major risk - Share price stability

Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now

JanOne Receives Non-Compliance Notice from the Nasdaq Stock Market

JanOne Inc., Annual General Meeting, Oct 09, 2023

New minor risk - Share price stability

New major risk - Earnings quality

Janone Inc. Files International Patent Application for Methods of Using Low Dose Naltrexone to Treat Chronic Pain

JanOne Inc. announced delayed 10-Q filing

Full year 2022 earnings released: EPS: US$1.14 (vs US$6.35 loss in FY 2021)

JanOne Received A Notice from the NASDAQ Stock Market

Third quarter 2022 earnings released: US$0.66 loss per share (vs US$0.34 loss in 3Q 2021)

High number of new and inexperienced directors

JanOne Inc., Annual General Meeting, Nov 02, 2022

JanOne Inc. (NasdaqCM:JAN) enter into a term sheet to acquire Soin Therapeutics LLC Soin Therapeutics LLC for $30 million.

JanOne to acquire Soin Therapeutics

Does JanOne (NASDAQ:JAN) Have A Healthy Balance Sheet?

Second quarter 2022 earnings released: EPS: US$3.39 (vs US$2.07 loss in 2Q 2021)

JanOne Inc. Announces an Improved Formulation of JAN101

JanOne Inc. Announces the Issuance of U.S. Patent Covering A Method of Improving Nerve Function Using Jan101

First quarter 2022 earnings released: EPS: US$0.43 (vs US$0.26 in 1Q 2021)

High number of new and inexperienced directors

JanOne Receives Notice from Nasdaq for Not Complying with Listing Rules

Full year 2021 earnings released: US$6.35 loss per share (vs US$4.59 loss in FY 2020)

Health Check: How Prudently Does JanOne (NASDAQ:JAN) Use Debt?

Is JanOne (NASDAQ:JAN) Using Debt In A Risky Way?

Third quarter 2021 earnings released: US$0.34 loss per share (vs US$0.43 loss in 3Q 2020)

High number of new and inexperienced directors

Janone Janone Inc. Revises Its Development Strategy Regarding Phase 2B Clinical Trial Design of Lead Drug Candidate Jan101

Janone Inc. Readies Clinical Supply of Lead Product Candidate Jan101 for Distribution to Phase 2B Trial Sites

JanOne Selects Regulatory Partner for Phase 2B Trial as Investigational Plan Is Prepared for FDA Filing

JanOne adds Nicholas Goeders to scientific advisory board

JanOne Announces Initiation of Phase 2b Peripheral Artery Disease Trial for Lead Product Candidate JAN101

JanOne advances toward initiation of mid-stage peripheral artery disease trial

Chief Financial Officer recently sold US$221k worth of stock

First quarter 2021 earnings released: EPS US$0.26 (vs US$1.33 loss in 1Q 2020)

Full year 2020 earnings released: US$4.59 loss per share (vs US$6.78 loss in FY 2019)

Virland Johnson entered into a definitive agreement to acquire substantially all assets and certain liabilities of ARCA Recycling, Inc. from JanOne Inc. (NasdaqCM:JAN) for $25 million.

JanOne Inc. has completed a Follow-on Equity Offering in the amount of $5.999994 million.

JanOne under pressure on pricing $6M stock offering

New 90-day high: US$5.47

New 90-day high: US$5.08

Third quarter 2020 earnings released: US$0.43 loss per share

New 90-day low: US$3.50

JanOne Begins Production of JAN101 cGMP Batch for Phase 2b Peripheral Artery Disease (PAD) Trial and Potential Covid-19 Study

New 90-day high - US$5.86

Earnings released

New 90-day high - US$3.74

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi